Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Authors
Keywords
PD-1, PD-L1, Expression, Immunosuppressive, Treatment, Glioma
Journal
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-04-07
DOI
10.1186/s13045-017-0455-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
- (2017) Jun Wang et al. Journal of Hematology & Oncology
- 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
- (2017) A. Amin et al. ANNALS OF ONCOLOGY
- Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
- (2016) Igor N. Ivashko et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
- (2016) Kuo-Hsing Chen et al. Journal of Hematology & Oncology
- Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
- (2016) Georgia J. B. McCaughan et al. Journal of Hematology & Oncology
- MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2
- (2016) De-Ning Ma et al. Journal of Hematology & Oncology
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
- (2016) Sarah T. Garber et al. NEURO-ONCOLOGY
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
- (2015) Feifei Teng et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
- (2015) Xi Wang et al. CELLULAR SIGNALLING
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
- (2015) Frauke M. Schnorfeil et al. Journal of Hematology & Oncology
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials
- (2015) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- 143 The Combination of anti-TIM-3 and anti-PD-1 Checkpoint Inhibitors With Focused Radiation Resulted in a Synergistic Antitumor Immune Response in a Preclinical Glioma Model
- (2015) Jennifer E. Kim et al. NEUROSURGERY
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
- (2015) Kavitha Gowrishankar et al. PLoS One
- The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
- (2015) Bo Yuan Huang et al. PLoS One
- Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
- (2014) Miguel F. Sanmamed et al. CANCER JOURNAL
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
- (2014) N.A. Rizvi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The role of IDO in brain tumor immunotherapy
- (2014) Lijie Zhai et al. JOURNAL OF NEURO-ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
- (2013) O. Bloch et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
- (2013) Y. Liu et al. JOURNAL OF NEUROSCIENCE
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Strength of PD-1 signaling differentially affects T-cell effector functions
- (2013) F. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Genetics of adult glioma
- (2012) McKinsey L. Goodenberger et al. Cancer Genetics
- Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
- (2011) Jiao Chen et al. IMMUNOBIOLOGY
- Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties
- (2011) Jennifer C. Rodrigues et al. NEURO-ONCOLOGY
- Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy
- (2010) K. Gousias et al. JOURNAL OF NEUROIMMUNOLOGY
- Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions
- (2010) Tony Avril et al. JOURNAL OF NEUROIMMUNOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MicroRNAs: Target Recognition and Regulatory Functions
- (2009) David P. Bartel CELL
- Honokiol-mediated Inhibition of PI3K/mTOR Pathway
- (2009) Courtney Crane et al. JOURNAL OF IMMUNOTHERAPY
- B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells
- (2009) Yu Yao et al. NEURO-ONCOLOGY
- Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion
- (2009) Seunggu J. Han et al. NEUROREPORT
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now